Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi- institutional update Academic Article uri icon

Overview

MeSH Major

  • Decision Support Techniques
  • Prostate-Specific Antigen
  • Prostatic Neoplasms

abstract

  • The data represent a multi-institutional modeling and validation of the clinical utility of combining PSA level measurement, clinical stage, and Gleason score to predict pathological stage for a group of men with localized prostate cancer. Clinicians can use these nomograms when counseling individual patients regarding the probability of their tumor being a specific pathological stage; this will enable patients and physicians to make more informed treatment decisions based on the probability of a pathological stage, as well as risk tolerance and the values they place on various potential outcomes.

publication date

  • May 14, 1997

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 9145716

Additional Document Info

start page

  • 1445

end page

  • 51

volume

  • 277

number

  • 18